Trial Profile
A retrospective study evaluating factors associated with poor response to Aflibercept therapy in neovascular age-related macular degeneration patients previously treated with Ranibizumab or Bevacizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Jul 2017
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Therapeutic Use
- 12 Jul 2017 New trial record